Sep–Dec 2023 • Vol LXII • No. 5 5 Pilex® in the Treatment and Management of Hemorrhoids Pilex® (TABLET) The medical answer to a surgical problem Pilex tablet is an Ayurvedic proprietary formulation recommended for the management of hemorrhoids. Pilex tablet has anti-inflammatory, analgesic, wound-healing, antimicrobial, hemostatic, laxative, and antioxidant actions. The ingredients of Pilex tablet act synergistically to bring about a reduction of the hemorrhoidal mass and facilitate early resolution of symptoms such as rectal bleeding, pain, and itching, and help correct the constipation associated with hemorrhoids. This clinical study was conducted to evaluate the efficacy of Pilex tablets in the treatment and management of hemorrhoids. The study enrolled 11 patients, of whom 4 patients had third-degree hemorrhoids, and 7 patients had fourth-degree hemorrhoids. The duration of hemorrhoids in the patients varied from 3 months to 8 years. Prior to the study, the patients were operated upon for associated conditions such as acute retention of urine (due to benign prostatic hyperplasia), acute intestinal obstruction, perforated peptic ulcer, and obstructed inguinal hernia. Sphincter dilatation of the anal canal was also performed immediately after the surgery. Pilex treatment was started 3 to 5 days after the surgery. The patients received 2 tablets of Pilex, TID, for 4 to 6 weeks. The patients also received an ounce of liquid paraffin at bedtime. After discharge, the patients were followed up fortnightly for regression of the hemorrhoidal mass and improvement in bleeding, pain, itching, discomfort, and proctoscopic findings, for 6 months. At the end of 6 to 8 weeks, complete relief from pain, discomfort, and bleeding was observed in all the patients. Complete regression of the hemorrhoidal mass was recorded in 9 patients. Control of congestion and reduction in the size of the hemorrhoidal mass were also observed. All the patients were in good physical health during the follow-up period. Overall, a remarkable improvement in the symptoms of hemorrhoids was observed in the patients. Thus, the results show that Pilex tablets are effective in the treatment and management of advanced degrees of hemorrhoids. An open-label, clinical study was conducted to evaluate the safety and efficacy of Pilex tablet in the treatment and management of external and internal hemorrhoids. The study enrolled 50 patients (aged 22–63 y; both men and women), of whom 31 patients had external hemorrhoids, 10 patients had internal hemorrhoids, and 9 patients had both internal and external hemorrhoids. All patients received 1 Pilex tablet, BID, for 6 weeks. Concomitant treatment with other hemorrhoidal drugs was discontinued during the study period. Proctoscopic examination was done before and at every fortnightly follow-up during the treatment period. During the follow-ups, the patients were evaluated for the reduction in the size of the hemorrhoidal mass, pain during defecation, bleeding during defecation, anal pruritus, strenuous bowel movements, and loss of appetite. The intensity of the signs and symptoms were graded on a 4-point scale as 0, absent; 1, mild; 2, moderate; and 3, severe. At the end of the study, the efficacy of the treatment was recorded as either very good, good, or not effective. Thirty-two patients completed the treatment, while the remaining patients were lost to follow-up. Treatment with Pilex tablets showed a significant reduction in the symptoms of hemorrhoids such as pain and bleeding and a significant improvement in the general health of the patients. The treatment response was recorded as very good in 56.25% of the patients and good in 37.50% of the patients. No observable side effects were noticed during the study. Thus, the study confirmed that Pilex tablets are safe and effective in the treatment and management of mild-to-moderate hemorrhoids. Clinical Evidence 2 An excerpt of the clinical study conducted by Vastrad CS et al published in the journal The Antiseptic is featured here. Clinical Evidence 1 An excerpt of the clinical study conducted by Belokar WK published in Probe is featured here.
RkJQdWJsaXNoZXIy MjAwNDg=